<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19471" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cholinergic Crisis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adeyinka</surname>
            <given-names>Adebayo</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kondamudi</surname>
            <given-names>Noah P.</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai , The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adebayo Adeyinka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noah Kondamudi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19471.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>A cholinergic crisis develops as a result of overstimulation of nicotinic and muscarinic receptors at the neuromuscular junctions. This is usually secondary to the inactivation or inhibition of acetylcholinesterase (AChE), the enzyme responsible for the degradation of acetylcholine (ACh). Excessive accumulation of acetylcholine (ACh) at the neuromuscular junctions and synapses causes symptoms of both muscarinic and nicotinic toxicity. These include cramps, increased salivation, lacrimation, muscular weakness, paralysis, muscular fasciculation, diarrhea, and blurry vision. This activity examines the presentation and evaluation of a patient undergoing a cholinergic crisis and the role of the health professional team in coordinating the care of this acute condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the history and physical exam findings typically seen in patients with cholinergic crisis.</p></list-item><list-item><p>Review how to evaluate for cholinergic crisis.</p></list-item><list-item><p>Identify the components involved in the management of a cholinergic crisis.</p></list-item><list-item><p>Outline interprofessional team strategies to improve care coordination and communication to enhance outcomes for patients affected by cholinergic crisis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19471&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19471">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19471.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cholinergic crisis is a clinical condition that develops as a result of overstimulation of nicotinic and muscarinic receptors at the neuromuscular junctions and synapses. This is usually secondary to the inactivation or inhibition of acetylcholinesterase (AChE), the enzyme responsible for the degradation of acetylcholine (ACh). Excessive accumulation of acetylcholine (ACh)&#x000a0;at the neuromuscular junctions and synapses causes symptoms of both muscarinic and nicotinic toxicity. These include&#x000a0;cramps, increased salivation, lacrimation, muscular weakness, paralysis, muscular fasciculation, diarrhea, and blurry vision<xref ref-type="bibr" rid="article-19471.r1">[1]</xref><xref ref-type="bibr" rid="article-19471.r2">[2]</xref><xref ref-type="bibr" rid="article-19471.r3">[3]</xref>.</p>
        <p>In clinical practice, this condition is most commonly seen in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with myasthenia gravis on treatment with&#x000a0;high dose acetylcholinesterase inhibitors.</p>
          </list-item>
          <list-item>
            <p>Patients after general anesthesia who received high doses acetylcholinesterase inhibitors to reverse the effects of&#x000a0;neuromuscular blocking agents, for example, neostigmine.</p>
          </list-item>
          <list-item>
            <p>Exposure to a chemical substance that causes inactivation of acetylcholinesterase. Examples of such substances are nerve gas like sarin, tabun, soman and other organophosphates like pesticides and insecticides.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19471.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Several clinical conditions can trigger a cholinergic crisis. Outlined below are the most commonly encountered disorders:</p>
        <p>
<bold>Overmedication with Acetylcholine Esterase Inhibitors AChEI in the Treatment of Myasthenia Gravis</bold>
</p>
        <p>Myasthenia gravis (MG) is&#x000a0;an autoimmune condition that affects the neuromuscular junction by producing autoantibodies against the ACh receptors at the postsynaptic membrane<xref ref-type="bibr" rid="article-19471.r4">[4]</xref>. This clinical disorder is characterized by generalized weakness or easy fatigability that can rapidly progress to respiratory failure<xref ref-type="bibr" rid="article-19471.r5">[5]</xref>. Another form of MG&#x000a0;commonly seen in women is associated with the production of antibodies against muscle-specific tyrosine kinase (MuSK)<xref ref-type="bibr" rid="article-19471.r6">[6]</xref><xref ref-type="bibr" rid="article-19471.r7">[7]</xref>.</p>
        <p>One of the treatment modalities for myasthenia gravis is the use of acetylcholinesterase inhibitors (AChEI) such as pyridostigmine. AChEI prevents the breakdown of ACh by inactivating AChE. This&#x000a0;stops the breakdown of ACh and increases&#x000a0;its level and duration of action at the postsynaptic membrane. Excessive use of AChEI in the treatment of a patient with MG may precipitate a cholinergic crisis which is characterized by both muscarinic and nicotinic toxicity<xref ref-type="bibr" rid="article-19471.r2">[2]</xref>.</p>
        <p>Myasthenic crisis is a complication of MG.&#x000a0;Precipitants of the myasthenic crisis include infection, surgery, menstruation, and certain medications like quinidine, calcium channel blockers (verapamil, nifedipine, felodipine) and antibiotics (gentamicin, ampicillin, streptomycin, erythromycin, ciprofloxacin)<xref ref-type="bibr" rid="article-19471.r8">[8]</xref><xref ref-type="bibr" rid="article-19471.r9">[9]</xref>. The clinical symptomatology of myasthenic crisis and cholinergic crisis are very similar. The cholinergic crisis should always be considered in myasthenic crisis although the cholinergic crisis is not that common in myasthenia crisis<xref ref-type="bibr" rid="article-19471.r10">[10]</xref><xref ref-type="bibr" rid="article-19471.r11">[11]</xref><xref ref-type="bibr" rid="article-19471.r12">[12]</xref>.</p>
        <p>It is important to identify which of the two conditions is causing muscular weakness. A simple test that can be done involves giving a dose of edrophonium, 2 mg intravenous. The medication produces clinical improvement in myasthenic crisis but worsening of symptoms in cholinergic crisis</p>
        <p>
<bold>Exposure to Organophosphates</bold>
</p>
        <p>Cholinergic crisis&#x000a0;can be precipitated&#x000a0;by exposure to drugs that inhibit AChE, for example, nerve gas and organophosphate compounds used in pesticides, insecticides, and herbicides. Exposure might be via inhalation of vapors, ingestion, or direct contact of the chemical with the skin or mucous membrane<xref ref-type="bibr" rid="article-19471.r13">[13]</xref><xref ref-type="bibr" rid="article-19471.r14">[14]</xref>.</p>
        <p>Organophosphates are chemical compounds&#x000a0;used extensively as agents of chemical warfare. Nerve gases are one of the deadliest agents in chemical warfare. Examples of such chemicals are sarin, tabun, soman, GF, and VX. Organophosphates work by inhibiting the action of AChE. This causes excessive stimulation of muscarinic and nicotinic receptors at the postsynaptic membrane. ACh binds to the endplates of smooth muscles and secretory glands causing nausea, vomiting, bronchospasm, miosis, blurry vision, bronchorrea, and sialohorrea. Nicotinic effect on skeletal muscle can cause fasciculation and flaccid paralysis. Nerve gas poisoning can vary in severity from mild to moderate or severe.</p>
        <p>Acute or chronic exposure to pesticides and insecticides containing organophosphates also&#x000a0;can&#x000a0;trigger a cholinergic crisis. Commonly used insecticides are malathion, parathion, diazinon, fenthion, and trichlorfon. Typically, patients are encountered in rural settings where pesticides and herbicides are used extensively. Examples of pesticides apart from organophosphates are carbamate, organochlorine, and pyrethroid insecticides. Apart from the muscarinic and nicotinic effects seen in cholinergic crisis, patients exposed to organophosphates might also exhibit neurological symptoms like a headache, dizziness, tremor, and paresthesia<xref ref-type="bibr" rid="article-19471.r15">[15]</xref>.</p>
        <p>
<bold>Reversal of Neuromuscular Blockage</bold>
</p>
        <p>Lastly, use of a reversal agent&#x000a0;like neostigmine or pyridostigmine&#x000a0;for neuromuscular blockages can also trigger a cholinergic crisis<xref ref-type="bibr" rid="article-19471.r16">[16]</xref><xref ref-type="bibr" rid="article-19471.r17">[17]</xref>. Neostigmine is a compound that inhibits AChE and is commonly used to reverse the effects of non-depolarizing paralytic agents like vecuronium, rocuronium, mivacurium, and pancuronium. Inhibiting AChE allows for the accumulation of ACh at the neuromuscular junction thus overcoming the competitive inhibition of non-depolarizing blocking agents. Neostigmine, like other AChE inhibitors, can stimulate the muscarinic receptors and cause the cholinergic crisis. Bronchospasm, miosis, increased peristalsis, and secretions are usually seen after administration of neostigmine. To minimize these effects on muscarinic receptors, an anticholinergic agent like glycopyrrolate is concomitantly administered during reversal of neuromuscular blocking agents.</p>
      </sec>
      <sec id="article-19471.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Data on the epidemiology of cholinergic crisis is very scant. Nevertheless, it is a known fact that cholinergic crisis is commonly seen in the pediatric population and patients with myasthenia gravis. In the pediatric age group, this crisis is usually as a result of accidental contact or ingestion of organophosphates. Children living in rural areas are at a very high risk. Since 2013, there are stricter federal regulations in the United States for the sale of organophosphates.</p>
        <p>Globally, about three million people have been exposed to organophosphate poisoning annually with approximately 300,000 deaths. Poisoning is from either accidental or intentional ingestion of agricultural insecticides or pesticides. In cholinergic crisis related to organophosphates, poisoning can be sourced to food products like wheat, flour, cooking oil, fruits, and vegetables.</p>
        <p>Since World War II, production of nerve gases like sarin and tabun has been limited. Manufacturing nerve gasses has been considered a war crime since the&#x000a0;Geneva Convention in 1925<xref ref-type="bibr" rid="article-19471.r2">[2]</xref>. Decreased production has significantly reduced the incidence of nerve gas poisoning in modern times. The most recent large-scale use of nerve gas was in Syria in 2013<xref ref-type="bibr" rid="article-19471.r15">[15]</xref>.</p>
      </sec>
      <sec id="article-19471.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Synthesis of the Neurotransmitter Acetylcholine</bold>
</p>
        <p>Cholinergic crisis is caused by overstimulation of the postsynaptic membrane by the neurotransmitter acetylcholine&#x000a0;(ACh). ACh is a chemical substance that was first proven to be a neurotransmitter by Loewi in 1921. ACh is found in at the synapses of ganglia, the neuromuscular junction, and the muscular system of the visceral organs. It is synthesized at the nerve terminal from acetyl coenzyme A (acetyl CoA).</p>
        <p>Acetyl CoA is derived from glucose and choline by a reaction catalyzed by choline acetyltransferase (CAT). ACh is then packaged in the presynaptic membrane in vesicles. Each vesicle can contain up to about 10,000 molecules of ACh which is subsequently released upon stimulation. Calcium ion stimulates the release of ACh. The action of ACh at the postsynaptic membrane is not terminated by reuptake of the neurotransmitter but rather by the action of a powerful hydrolytic enzyme acetylcholine esterase AChE. This enzyme is found in the synaptic cleft. The action of this enzyme breaks up ACh into choline and acetate. The cholinergic nerve terminal has a sodium choline transporter that takes up choline produced from hydrolysis of ACh<xref ref-type="bibr" rid="article-19471.r18">[18]</xref><xref ref-type="bibr" rid="article-19471.r19">[19]</xref>.</p>
        <p>ACh acts on both muscarinic and nicotinic receptors.</p>
        <p>Muscarinic receptors are located throughout the body. They are activated by the action of muscarine and ACh. These receptors are part of the G protein-coupled receptors. On activation, there is an increase in intracellular cyclic adenosine monophosphate (AMP). Activation of cyclic AMP triggers the action of protein kinase. The muscarinic receptors form part of the parasympathetic that helps with the regulation of secretions (both in the bronchial tree and the gastrointestinal tract), heart rate, pupillary response,&#x000a0;and urination.</p>
        <p>
<bold>Muscarinic Effects of ACh</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Eye miosis and blurry vision,</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal system: nausea, vomiting, and diarrhea</p>
          </list-item>
          <list-item>
            <p>Respiratory system: low lung compliance, bronchoconstriction, and bronchorrhea</p>
          </list-item>
          <list-item>
            <p>Secretory system: increased secretions in the tracheobronchial and gastrointestinal system</p>
          </list-item>
          <list-item>
            <p>Cardiovascular system: bradycardia</p>
          </list-item>
          <list-item>
            <p>Genitourinary: urinary frequency and urgency</p>
          </list-item>
        </list>
        <p>Nicotinic receptors belong to the ligand-gated ion family of receptors. They are stimulated by ACh and nicotine. They are located in muscle fiber at the neuromuscular junctions and autonomic ganglia for both the sympathetic and parasympathetic nervous systems&#x000a0;<xref ref-type="bibr" rid="article-19471.r2">[2]</xref>.</p>
        <p>
<bold>Nicotinic Effects of ACh</bold>
</p>
        <p>ACh binds to the endplate of skeletal muscle and synaptic ganglia causing the following effects</p>
        <list list-type="bullet">
          <list-item>
            <p>Voluntary muscle fasciculation: flaccid paralysis</p>
          </list-item>
          <list-item>
            <p>Cardiovascular effects: tachycardia that may progress to bradycardia from the opposing effects of the stimulation of muscarinic and nicotinic receptors.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19471.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The diagnostic work of cholinergic crisis can pose a clinical challenge, especially for those unfamiliar with the clinical signs and symptoms. A very detailed history taking with a thorough physical examination is necessary. In the physical examination, particular attention should be paid to the nervous, respiratory, cardiovascular, and gastrointestinal system as this is where the clinical manifestation is most profound.&#x000a0; A good mnemonic to remember is<bold> SLUDGEM</bold> and<bold> DUMBELS</bold> for the muscarinic effect of ACh.</p>
        <p>
<bold>Clinical Findings Related to Stimulation of Muscarinic Receptors</bold>
</p>
        <p><bold>S</bold>- Salivation</p>
        <p><bold>L</bold>- Lacrimation</p>
        <p><bold>U</bold> -Urinary frequency</p>
        <p><bold>D</bold>-Diarrhea</p>
        <p><bold>G</bold>- Gastrointestinal cramping and pain</p>
        <p><bold>E</bold>- Emesis</p>
        <p><bold>M</bold>- Miosis</p>
        <p>Another mnemonic that is commonly used for symptoms is "DUMBELS."</p>
        <p><bold>D</bold>- Diaphoresis and Diarrhea</p>
        <p><bold>U</bold> -Urinary frequency</p>
        <p><bold>M</bold>-Miosis</p>
        <p><bold>B</bold>-Bronchospasm and Bronchorrhea</p>
        <p><bold>E</bold> &#x02013; Emesis</p>
        <p><bold>L</bold> &#x02013; Lacrimation</p>
        <p><bold>S</bold> &#x02013; Salivation</p>
        <p>
<bold>Clinical Findings Related to Stimulation of Nicotinic Receptors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Muscular weakness</p>
          </list-item>
          <list-item>
            <p>Muscular fatigue and fasciculation</p>
          </list-item>
          <list-item>
            <p>Respiratory muscle weakness</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
        </list>
        <p><bold>Clinical Findings Related to Stimulation&#x000a0;of &#x000a0;the</bold>
<bold>Central Nervous System </bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Slurred speech</p>
          </list-item>
          <list-item>
            <p>Agitation and restlessness</p>
          </list-item>
        </list>
        <p>Clinical diagnosis of cholinergic crisis can be established based on the toxidromes listed above.</p>
        <p>In the history taking, it is very pertinent to determine the cause of the cholinergic crises:</p>
        <list list-type="bullet">
          <list-item>
            <p>Medications for the treatment of myasthenia gravis or glaucoma, including pyridostigmine</p>
          </list-item>
          <list-item>
            <p>Ingestion or exposure to insecticides, pesticides,&#x000a0; or herbicides</p>
          </list-item>
          <list-item>
            <p>Exposure to nerve gas</p>
          </list-item>
          <list-item>
            <p>Reversal of neuromuscular blockage</p>
          </list-item>
        </list>
        <p>Time is paramount in the initial assessment. When, how, and where the ingestion or exposure took place is necessary to elicit from the history. This is because&#x000a0;there is&#x000a0;a 48-hour window during which to administer pralidoxime as an antidote. Pralidoxime will react with the enzyme that breaks down ACh&#x000a0;after contact with the inhibitor of AChE, in this instance the nerve gas or insecticide. The reactivated enzyme AChE will expedite the molecular&#x000a0;degradation of ACh. The degradation of ACh will terminate the overstimulation of the postsynaptic membrane by ACh.</p>
      </sec>
      <sec id="article-19471.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of patients with cholinergic crisis involves a detailed history taking and physical examination for the toxidromes associated with the crisis.</p>
        <p>Included in the evaluation are ancillary studies:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Complete Blood Count (CBC)</bold>&#x000a0;to check if there is an elevation of white blood cell count to rule out an infectious process.</p>
          </list-item>
          <list-item>
            <p><bold>Comprehensive Metabolic Panel (CMP)</bold>&#x000a0;to rule out electrolytes abnormalities related to organophosphate poisoning</p>
          </list-item>
          <list-item>
            <p><bold>Red Blood Cell Cholinesterase activity</bold>&#x000a0;is usually decreased, and this can help in confirming the diagnosis. Plasma pseudocholinesterase can also be used but is less accurate than red blood cell cholinesterase activity<xref ref-type="bibr" rid="article-19471.r20">[20]</xref>.</p>
          </list-item>
          <list-item>
            <p><bold>Electrocardiography&#x000a0;</bold>to check for the presence of arrhythmia associated with organophosphate poisoning.</p>
          </list-item>
          <list-item>
            <p><bold>Chest X-Ray</bold>&#x000a0;to evaluate&#x000a0;for the presence of pulmonary edema or aspiration.</p>
          </list-item>
          <list-item>
            <p><bold>Head CAT scan</bold>&#x000a0;is indicated if the patient's mental status is altered or there are significant changes in the Glasgow Coma Scale.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19471.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of cholinergic crisis&#x000a0;encompasses three stages: (1) prehospital care, (2) emergency department management, and (3) Inpatient care.</p>
        <p>
<bold>Prehospital Care</bold>
</p>
        <p>Prehospital care includes the initial stabilization of the patient and the removal of the offending toxic agent. Decontamination should be initiated as soon as possible&#x000a0;if poisoning with organophosphate or nerve gas is the primary culprit of cholinergic crisis. All clothing should be removed from the patient&#x02019;s body to prevent continued contamination and to prevent cross-contamination of first responders.</p>
        <p><bold>Emergency Room</bold>
<bold>Management</bold></p>
        <p>Regardless of the&#x000a0;etiology &#x000a0;of cholinergic crises, the core principle in stabilization is ABC: Airway, Breathing, and Circulation.</p>
        <p>
<bold>Airway and Breathing</bold>
</p>
        <p>Care should be taken to ensure that the airway is patent and the patient is breathing spontaneously. The airway should be secured if there is a concern for airway compromise.</p>
        <p>Indications for advanced airway management and intubation in cholinergic crisis are :</p>
        <list list-type="bullet">
          <list-item>
            <p>Copious oral and nasal &#x000a0;secretions compromising the patency of the airway</p>
          </list-item>
          <list-item>
            <p>Altered mental status with a Glasgow Coma Score less than 8&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Evidence of hemodynamic instability</p>
          </list-item>
          <list-item>
            <p>Profound weakness of the respiratory muscles</p>
          </list-item>
        </list>
        <p>
<bold>Circulation</bold>
</p>
        <p>Vascular access should be established immediately with two large-bore peripheral intravenous access. Fluid should be started to maintain adequate circulation with continuous pulse oximetry and monitoring of vital signs. In the case of hemodynamic instability, central venous access should be established for infusion of vasoactive medications.</p>
        <p>In the emergency department, the primary focus on initial management is the maintenance of the airway and hemodynamic stability. If the patient is already intubated, ventilatory support should be continued .</p>
        <p>
<bold>Inpatient Management</bold>
</p>
        <p>Inpatient care includes continued cardiopulmonary support and monitoring. Patients with a cholinergic crisis should be admitted to the intensive care unit.</p>
        <p>
<bold>Antidotes for cholinergic crisis</bold>
</p>
        <p>Two types of antidotes are used for a cholinergic crisis: atropine and oximes.</p>
        <p>
<italic toggle="yes">
<bold>Atropine</bold>
</italic>
</p>
        <p>The first antidote is atropine. It is an effective agent for the muscarinic effect of acetylcholine. It competitively binds to the postsynaptic muscarinic receptor thereby preventing further action of ACh. Atropine dose is about 0.03- 0.05 mg/kg for pediatric and about 2 mg for&#x000a0;adult&#x000a0;patients. It is recommended to give atropine until signs of atropinization is present:</p>
        <p>
<italic toggle="yes">Signs of atropinization</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Warm, dry, and flushed skin</p>
          </list-item>
          <list-item>
            <p>Mydriasis &#x000a0;</p>
          </list-item>
        </list>
        <p>Atropine does not have any effect on the nicotinic receptors.</p>
        <p>
<italic toggle="yes">
<bold>Oximes</bold>
</italic>
</p>
        <p>For the nicotinic effect in cholinergic crisis, the antidote is a class of drugs called the &#x0201c;oximes.&#x0201d; Examples of oximes are pralidoxime and obidoxime<xref ref-type="bibr" rid="article-19471.r21">[21]</xref>.</p>
        <p>In the United States, pralidoxime chloride is the most commonly used antidote. Its mechanism of action is like that of a "molecular crowbar" that separates the bonded nerve gas or organophosphate from acetylcholinesterase. The separated AChE can then continue the process of chemical breakdown of ACh. There is a window period during which oximes can be given before there is an irreversible bonding of nerve gas to AChE. This phenomenon is known as "aging<xref ref-type="bibr" rid="article-19471.r22">[22]</xref>." The aging half-life ranges from two minutes for soman to several hours for sarin</p>
        <p>Pralidoxime should be given to patients with signs of respiratory muscle weakness or generalized muscular weakness.&#x000a0;It should be administered until there is an improvement in muscle weakness.&#x000a0;It does not cross the blood-brain barrier hence the central nervous system effect of organophosphate poisoning is not neutralized. This is achieved by using atropine.</p>
        <p>
<bold>Other medications in cholinergic crisis</bold>
</p>
        <p>Seizure and agitation in cholinergic crisis can be treated with benzodiazepine-like midazolam or lorazepam. Care should also be taken to avoid drugs like loop diuretics, theophylline, and caffeine and succinylcholine in organophosphate poisoning as this can make the symptoms of toxicity worse.</p>
        <p>In the management of cholinergic crisis secondary to reversal of neuromuscular blockage with neostigmine, atropine or glycopyrrolate can be administered to lessen the cholinergic effects of the neuromuscular blockage reversal.</p>
        <p>Consultation with a clinical toxicologist and intensivist is recommended in&#x000a0;the treatment of cholinergic crisis.</p>
      </sec>
      <sec id="article-19471.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The myasthenic crisis should be differentiated from the cholinergic crisis with edrophonium test. Administration of 2 mg of edrophonium will worsen the clinical symptom in cholinergic crisis. The contrary is the case in myasthenic crisis. Other causes of cholinergic crisis like exposure to nerve gas, organophosphates and use of reversal agent for neuromuscular blockage should be considered in the differential diagnosis.</p>
      </sec>
      <sec id="article-19471.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The mortality rate in cholinergic crisis ranges from 3% to 25% The most common cause of death is progressive respiratory failure.</p>
      </sec>
      <sec id="article-19471.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The following complications can develop in cholinergic crisis. These problems are related to the overstimulation of the muscarinic and nicotinic receptors.</p>
        <p>Outlined below are the complications as it affects each system.</p>
        <p>
<bold>Respiratory System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory failure from profound weakness of respiratory muscles</p>
          </list-item>
          <list-item>
            <p>Aspiration pneumonia from hypersalivation and bronchorrhea</p>
          </list-item>
          <list-item>
            <p>Severe bronchospasm</p>
          </list-item>
        </list>
        <p>
<bold>Cardiovascular System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Arrhythmia</p>
          </list-item>
        </list>
        <p>
<bold>Central Nervous System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hallucination</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Seizure</p>
          </list-item>
          <list-item>
            <p>Altered mental status</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrolytes abnormalities related to gastrointestinal losses from vomiting and diarrhea</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19471.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A detailed knowledge of cholinergic crisis is required for proper management. To improve patients outcome an interprofessional approach of&#x000a0;nurses,&#x000a0;physician assistants, and physicians is required for the treatment especially when this is related to poisoning. A good resource to use in management is the Poison Control Center</p>
      </sec>
      <sec id="article-19471.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19471&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19471">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/nerve-health/cholinergic-crisis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19471">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19471/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19471">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19471.s14">
        <title>References</title>
        <ref id="article-19471.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kothari</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Myasthenia gravis.</article-title>
            <source>J Am Osteopath Assoc</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>9</issue>
            <fpage>377</fpage>
            <page-range>377-84</page-range>
            <pub-id pub-id-type="pmid">15452103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacomis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Myasthenic crisis.</article-title>
            <source>Neurocrit Care</source>
            <year>2005</year>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-94</page-range>
            <pub-id pub-id-type="pmid">16377829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silvestri</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Bromberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lacomis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>What's in the Literature?</article-title>
            <source>J Clin Neuromuscul Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>227</fpage>
            <page-range>227-38</page-range>
            <pub-id pub-id-type="pmid">27224441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Behan</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>Myasthenic crisis.</article-title>
            <source>QJM</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-107</page-range>
            <pub-id pub-id-type="pmid">19060020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zivkovi&#x00107;</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lacomis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of late-onset myasthenia gravis.</article-title>
            <source>J Neurol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>259</volume>
            <issue>10</issue>
            <fpage>2167</fpage>
            <page-range>2167-71</page-range>
            <pub-id pub-id-type="pmid">22476514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>519</fpage>
            <page-range>519-25</page-range>
            <pub-id pub-id-type="pmid">16155434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alboini</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Damato</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Iorio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Provenzano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bartoccioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Myasthenia gravis with antibodies to MuSK: an update.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>1412</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-89</page-range>
            <pub-id pub-id-type="pmid">29266255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>[Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].</article-title>
            <source>Zhonghua Yi Xue Za Zhi</source>
            <year>2013</year>
            <month>May</month>
            <day>07</day>
            <volume>93</volume>
            <issue>17</issue>
            <fpage>1283</fpage>
            <page-range>1283-6</page-range>
            <pub-id pub-id-type="pmid">24029473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Permanent Peripheral Neuropathy: A Case Report on a Rare but Serious Debilitating Side-Effect of Fluoroquinolone Administration.</article-title>
            <source>J Investig Med High Impact Case Rep</source>
            <year>2014</year>
            <season>Jul-Sep</season>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>2324709614545225</fpage>
            <pub-id pub-id-type="pmid">26425618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wendell</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Myasthenic crisis.</article-title>
            <source>Neurohospitalist</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-22</page-range>
            <pub-id pub-id-type="pmid">23983833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HOKKANEN</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>ANTIBIOTICS IN MYASTHENIA GRAVIS.</article-title>
            <source>Br Med J</source>
            <year>1964</year>
            <month>Apr</month>
            <day>25</day>
            <volume>1</volume>
            <issue>5390</issue>
            <fpage>1111</fpage>
            <page-range>1111-2</page-range>
            <pub-id pub-id-type="pmid">14113831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Calvert</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Aggravation of myasthenia gravis by erythromycin.</article-title>
            <source>Ann Neurol</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-9</page-range>
            <pub-id pub-id-type="pmid">2252369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newmark</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nerve agents.</article-title>
            <source>Neurologist</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-32</page-range>
            <pub-id pub-id-type="pmid">17215724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barthold</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Schier</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Organic phosphorus compounds--nerve agents.</article-title>
            <source>Crit Care Clin</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>673</fpage>
            <page-range>673-89, v-vi</page-range>
            <pub-id pub-id-type="pmid">16168308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastogi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ravishanker</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A study of neurologic symptoms on exposure to organophosphate pesticides in the children of agricultural workers.</article-title>
            <source>Indian J Occup Environ Med</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>54</fpage>
            <page-range>54-7</page-range>
            <pub-id pub-id-type="pmid">21120082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Neely</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sabir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Neostigmine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29261883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Reversal of neuromuscular block.</article-title>
            <source>Br J Anaesth</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-29</page-range>
            <pub-id pub-id-type="pmid">19468024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LOEWI</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>On the intraneural state of acetylcholine.</article-title>
            <source>Experientia</source>
            <year>1956</year>
            <month>Sep</month>
            <day>15</day>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>331</fpage>
            <page-range>331-3</page-range>
            <pub-id pub-id-type="pmid">13365584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LOEWI</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>On the background of the discovery of neurochemical transmission.</article-title>
            <source>J Mt Sinai Hosp N Y</source>
            <year>1957</year>
            <season>Nov-Dec</season>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1014</fpage>
            <page-range>1014-6</page-range>
            <pub-id pub-id-type="pmid">13481646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herkert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bumm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thiermann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Worek</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the oxime-induced reactivation of erythrocyte and muscle acetylcholinesterase following inhibition by sarin or paraoxon, using a perfusion model for the real-time determination of membrane-bound acetylcholinesterase activity.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2008</year>
            <month>Feb</month>
            <day>01</day>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>698</fpage>
            <page-range>698-703</page-range>
            <pub-id pub-id-type="pmid">17977518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eyer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The role of oximes in the management of organophosphorus pesticide poisoning.</article-title>
            <source>Toxicol Rev</source>
            <year>2003</year>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-90</page-range>
            <pub-id pub-id-type="pmid">15181665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19471.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burillo-Putze</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Duenas-Laita</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Late administration of pralidoxime in organophosphate (fenitrothion) poisoning.</article-title>
            <source>Am J Emerg Med</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-8</page-range>
            <pub-id pub-id-type="pmid">15258887</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
